MOA Life Plus Co. Ltd. (KOSDAQ:142760)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,051.00
+55.00 (5.52%)
At close: Apr 3, 2026
Market Cap42.89B -9.9%
Revenue (ttm)11.22B -28.2%
Net Income-13.05B
EPS-340.00
Shares Out40.81M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume660,926
Average Volume488,112
Open996.00
Previous Close996.00
Day's Range968.00 - 1,070.00
52-Week Range577.00 - 2,250.00
Beta0.67
RSI63.88
Earnings DateMay 15, 2026

About MOA Life Plus

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw ma... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 42
Stock Exchange KOSDAQ
Ticker Symbol 142760
Full Company Profile

Financial Performance

In 2025, MOA Life Plus's revenue was 11.22 billion, a decrease of -28.24% compared to the previous year's 15.63 billion. Losses were -13.05 billion, 88.6% more than in 2024.

Financial Statements